Jupiter Life Line Hospitals reported a Q2 FY27 PAT of Rs 56.4 crore on revenues of Rs 456.5 crore. The board approved the Rs 150 crore acquisition of the Pune South hospital land, with a net cash outflow of Rs 100 crore. Notably, the Dombivli facility neared break-even, with EBITDA losses shrinking to Rs 0.2 crore from Rs 9.4 crore in Q1.
Jupiter Life Line Hospitals Q2 FY27 Performance Update
Q2 FY27 PAT stood at Rs 56.4 crore; Q2 FY27 Income reached Rs 456.5 crore.
Reader Takeaway: Strong operational recovery at the Dombivli unit provides a tailwind, though regulatory dependence for expansion remains a factor.
What just happened
Jupiter Life Line Hospitals has received board approval for the acquisition of the Pune South hospital land for a total consideration of Rs 150 crore. After accounting for a Rs 50 crore deposit, the company will undertake an incremental cash outflow of Rs 100 crore. Operationally, the company showed steady growth, with the Dombivli facility showing significant improvement, narrowing its EBITDA loss to Rs 0.2 crore from Rs 9.4 crore in the previous quarter.
Why this matters
The acquisition of the Pune South land secures the long-term future of the facility by transitioning from a leasehold to an ownership model. Meanwhile, the narrowing losses at Dombivli indicate successful ramp-up efforts, supported by seasonal patient influx. With net debt of approximately Rs 170 crore and cash-on-hand of Rs 400 crore, the company maintains a healthy balance sheet to fund further growth.
Business and Operational Updates
Expansion remains a key focus. The Mira Bhayandar project is advancing through regulatory stages, while the BKC unit is currently in the planning phase. In existing units, Thane and Pune facilities are performing well, with occupancy rates hovering around 70%. Management has signaled a conservative approach to the Indore facility, choosing to hold off on immediate expansion until occupancy reaches mid-60s thresholds.
Debt and Capex
The company maintains a disciplined financial policy with a self-imposed debt ceiling of 3x EBITDA. Internal accruals are expected to remain the primary funding source for upcoming capital expenditure.
Risks to watch
- Sustainability of the Dombivli break-even status as seasonal disease patterns normalize.
- Regulatory approval timelines for upcoming projects in Mira Bhayandar and BKC.
- Ongoing competition for specialized medical talent impacting operating expenses.
Context metrics (H1 FY27)
- Income: Rs 867.5 crore
- EBITDA: Rs 186.2 crore
- PAT: Rs 93.9 crore